PhaseBio

-$0.06 (-1.68%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell PhaseBio and other ETFs, options, and stocks.

About PHAS

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiopulmonary diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension.

CEO
Jonathan P. Mow
Employees
50
Headquarters
Malvern, Pennsylvania
Founded
2002

PHAS Key Statistics

Market Cap
172.42M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
188.19K
High Today
$3.58
Low Today
$3.43
Open Price
$3.58
Volume
155.04K
52 Week High
$5.83
52 Week Low
$2.60

PHAS Earnings

-$1.03
-$0.69
-$0.34
$0.00
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
— per share
Actual
Expected Aug 10, After Hours
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure